In response to increasing insulin requirements, concentrated insulins are currently being developed to address patient needs. 20 Recently developed concentrated insulins include insulin degludec (200 unit/mL formulation; Novo Nordisk, Bagsvaerd, Denmark), 21 insulin glargine (300 unit/ mL formulation; sanofi-aventis US LLC, Bridgewater, NJ, USA), 22 and insulin lispro (200 unit/mL; Eli Lilly and Company, Indianapolis, IN, USA). 23 The prefilled insulin delivery devices that contain these concentrated insulins dial and dose in actual units such that no conversion is needed based on the concentration. [21] [22] [23] The Humalog® 200 units/mL KwikPenTM.(insulin lispro 200 units/mL, hereafter, IL 200 pen; Eli Lilly and Company, Indianapolis, IN, USA) insulin delivery device was recently approved in the US 24 and in the European Union. 25 The IL 200 pen insulin delivery device delivers the same unit dose of insulin lispro (200 units/mL) in half the volume as the Humalog® 100 units/mL KwikPenTM (insulin lispro100 units/mL; hereafter, IL 100 pen; Eli Lilly and Company, Indianapolis, IN, USA). 23 Because the IL 200 pen contains 600 units of insulin as compared to the IL 100 pen with 300 units, patients can use the IL 200 pen for twice as many doses of insulin. 25 In addition, the glide force, or force to push the injection button, of the IL 200 pen is significantly lower than that of the IL 100 pen for the same dose. 23 The pens are designed to function similarly to facilitate patient ease of use. Both pens are primed in 2-unit increments, with the IL 200 pen priming in half the volume of the IL 100 pen. The purpose of this study was to examine which insulin device delivery option (IL 100 pen or IL 200 pen) was preferred among the intended user population of patients with diabetes who require greater than 20 units of mealtime insulin as well as diabetes caregivers. This study also determined which attributes had the greatest influence on pen preference selection.
Methods

Study design
This single-visit, 2-period, crossover, simulated-use preference study ( Figure 1 ) was conducted over a 3-week period across multiple clinical trial sites in the US in accordance with the Declaration of Helsinki and the International Conference on Harmonisation Guideline on Good Clinical Practices. 26 The protocol and informed consent form were reviewed and approved by an institutional review board. Data in this study were collected in accordance with industry best practices, regulatory guidances, and consensus standards that are considered reliable and accurate for human factor studies.
Study Participants
Participants were recruited by means of advertisements. Interested participants were prescreened by telephone to determine if they met study eligibility criteria. Adult patients at least 18 years old with T1DM or T2DM who self-administered, either by vial and syringe or injection pen, more than 20 units of mealtime (short-or rapid-acting) insulin per day were included in the study. Patients were excluded if they were physically unable to perform requested tests as determined during screening or only used an insulin pump to deliver insulin instead of a vial and syringe or pen.
Study Procedures
After informed consent was obtained, participants were randomly assigned to 1 of 8 sequences that varied the pen order (IL 100 pen or IL 200 pen) and the dosing order (15 units = low dose or 50 units = high dose) for a total of 4 simulated injections of saline ( Figure 1 ). Simulated injections involved asking the participant to prepare the IL 100 pen or the IL 200 pen, as applicable, and inject the appropriate dose into the injection pad.
Eligible participants received training on the first pen, including information about the insulin and the steps required to administer an injection (eg, attaching a needle, priming the pen, dialing a dose, and injecting), before the respective pen and instructions for use were provided to the participant. Participants then completed 2 sequential injections in a randomized order. The injection task began with the participant attaching a new needle to the pen, priming the pen, dialing the appropriate dose (15 or 50 units), and performing the injection into the injection pad and ended with the participant discarding the needle. After completing both injection tasks with the first pen, participants received training on the second pen and then completed 2 sequential injections of the same unit doses as the first pen in a randomized order. After finishing the 4 simulated injections, participants completed a self-administered questionnaire to evaluate their final preference between the 2 pens.
The questionnaire used in this study was adapted from existing insulin device assessment and preference questionnaires. It was modified specifically for this study to evaluate overall preference for the injection device and then evaluate aspects of the participant's device experience and specific features of the device that contributed to overall device preference. This questionnaire was adapted from items within the Insulin Device Assessment Battery and the Insulin Device Preference Battery, which were developed as patientcompleted tools to compare the characteristics of and patient preference for different insulin delivery devices. [27] [28] [29] Content validity has been established via cognitive debriefing of the original questionnaires. 27 The modified measures underwent cognitive debriefing testing in a pilot study with 4 participants to ensure comprehensiveness and comprehension of the preference question and attribute ratings in a population of patients who were using insulin.
The first section of the preference questionnaire evaluated overall preference with 3 response options (prefer IL 100 pen, prefer IL 200 pen, and no preference). The second section of the preference questionnaire presented participants with a list of 11 device features or attributes (Table 1) and asked them to rate the importance of these attributes in choosing their overall preference on a 5-point Likert-type scale where 1 corresponded to "not at all important" and 5 corresponded to "extremely important."
Statistical Analyses
A sample size of 114 participants was selected based on a 15% dropout rate with 97 participants needed to complete the study. Assuming a 33% rate of no preference, and assuming among those with a preference that the actual rate of preferring the IL 200 pen over the IL 100 pen is 70%, a minimum of 65 participants with preference were needed to show preference for the IL 200 pen over the IL 100 pen at 91% power (ie, demonstrate the primary objective). If the lower limit of an exact 95% 2-sided confidence interval (CI) for preference rate exceeded 50%, then the primary objective was met.
Baseline characteristics were summarized using descriptive statistics (frequencies, means, and standard deviations [SDs]). For the primary objective, descriptive statistics and a 95% CI were used to summarize the preference rate. The Wilson (score) CI for binomial proportion was used to test the null hypothesis (ie, preference rate ≤50%) for the primary objective. Only the primary objective was reported for all participants. Logistic regression models were used to test the effects of sequence (pen) and baseline characteristics on preference as sensitivity analyses.
For the secondary objectives, each question/item was summarized using descriptive statistics for the score (number of subjects, mean, SD, median, first quartile, third quartile, minimum, and maximum) and frequencies and percentages of response for each of the 5 response options. Ranking of attribute importance was based on the percentage of response for each of the 5 response options as well as the mean score. A mixed-model repeated measures analysis was used to compare the scores for the top 3 and top 5 attributes influencing pen preference, respectively. Fixed effects included the corresponding questions, sequence (pen), and baseline characteristics. Within-subject covariance structure was included in the model to account for the repeated-measure nature of the data (scores for different questions were related within subject). The adjustment for multiple testing (Tukey) was used to perform comparisons of scores between the top 3 or top 5 attributes influencing pen preference.
Results
Patient Disposition
A total of 106 participants signed and dated the informed consent form and were randomized to 1 of 8 sequences. Of those 106 randomized participants, 5 (4.7%) were discontinued from the study because it was determined that they were not self-administering more than 20 units of mealtime insulin per day (including any participants who were injecting an insulin mixture). The remaining 101 (95.3%) participants completed all 4 injections.
Patient Characteristics and Demographics of All Completers
Participants in this study had a mean age of 54 years, with similar numbers of males and females, and were primarily white ( Table 2 ). The majority of patients had been diagnosed with T2DM, had a mean duration of diabetes of 17 years, and self-administered their insulin injections. Baseline characteristics of the patients who completed the study were similar across the 3 groups (prefer IL 100 pen, prefer IL 200 pen, and no preference).
Primary Objective
Of the 90 participants expressing a preference, significantly more participants preferred the IL 200 pen than the IL 100 pen (Figure 2 ) (IL 200 pen: 80 participants; IL 100 pen 10 participants; 95% CI [0.81, 0.94], P < .0001), meeting the primary objective because the lower limit of the 95% CI exceeded 50%. The remaining 11 participants exhibited no 
Pen attribute
Easy to learn to use the pen Easy to follow instructions when using the pen Overall easy to use the pen Easy to read the dose Easy to press the button to inject Color of pen Total amount of insulin in the pen (number of units) Amount of liquid injected Shape of pen Easy to know I have selected the intended dose for injections Easy to prime the pen Adapted from items within the Insulin Device Assessment Battery and the Insulin Device Preference Battery. [27] [28] [29] preference for either insulin pen device. Sensitivity analyses of overall preference showed no significant effects of baseline characteristics (eg, age, race, duration of diabetes, sex, mealtime units, type of diabetes) on pen preference (data not shown). In addition, there was no effect of randomization sequence on pen preference.
Secondary Objectives
Among the 90 participants who exhibited a preference for either pen device, mean scores were calculated and used to rank all 11 questionnaire items from highest mean score (5 = "extremely important") to lowest mean score (1 = "not at all important"). The most important attributes influencing preference for IL 200 pen among the 80 participants were the total amount of insulin in the pen (#1) (mean ± SD: 4.16 ± 1.34), the injection button was easy to press (#2) (3.78 ± 1.64), the amount of fluid injected (#3) (3.61 ± 1.61), the overall ease in using the pen (#4) (3.25 ± 1.73), and the ease in reading the dose (#5) (2.90 ± 1.84). The shape (#10) (1.95 ± 1.43) and the color (#11) (1.71 ± 1.30) of the pen were the least important attributes (Figure 3) .
The most important attributes influencing preference for the IL 100 pen among the 10 participants were the injection button was easy to press (#1) (3.70 ± 1.77), the ease in knowing the intended dose (#2) (3.30 ± 2.00), the ease in reading the dose (#3) (3.20 ± 1.62), the overall ease in using the pen (#4) (3.10 ± 1.85), and total amount of insulin in the pen (#5) (2.90 ± 1.45). The shape (#10) (2.50 ± 1.78) and color (#11) (1.80 ± 1.32) of the pen were rated as the least important attributes (Figure 4) .
Comparison of the top 3 attributes influencing preference for the IL 200 pen based on the mean score depicted in Figure 3 showed a significant difference overall ( Table 3 , P = .0141). Pairwise comparisons showed a significant difference between the amount of fluid injected (#3) and the total amount of insulin in the pen (#1) (P = .0104) but not for the remaining pairwise comparisons. Comparison of the top 5 attributes influencing preference for the IL 200 pen based on the mean score showed a significant overall difference (P < .0001). Pairwise comparisons of these top 5 attributes were statistically significant, except for the amount of fluid injected (#3) and the overall ease in using the pen (#4), the amount of fluid injected (#3) and the injection button was easy to press (#2), and the total amount of insulin in the pen (#1) and the injection button was easy to press (#2).
Comparison of the top 3 attributes influencing preference for the IL 100 pen showed no significant overall differences (P = .2267). Similarly, there were no significant overall differences among the top 5 attributes (P = .1735).
In the IL 200 preference group, all questionnaire items were ranked based on the percentages of responses for each of the 5 response options. The ranking of items based on the percentage of participants who felt they were "extremely important" was identical to the mean score ranking. More than 50% of participants ranked the top 2 attributes relating to the IL 200 pen preference as "extremely important" (Figure 5 ): the total amount of insulin in the pen (#1) (64%) and the injection button was easy to press (#2) (55%).
Discussion
Most of the patients with diabetes requiring more than 20 units of mealtime insulin or diabetes caregivers preferred the IL 200 pen over the IL 100 pen, and this result met the primary objective. Key pen attributes influencing preference for the IL 200 pen included the total amount of insulin in the pen, the ease of pressing the injection button, and the amount of fluid injected, which are attributes specific to the higher concentration of insulin in the IL 200 pen. 23 Participants noted anecdotally that they liked the idea of using fewer pens (facilitated by more insulin in each pen), that the pen button was easier to push (due to decreased glide force), and that an injection would be delivered in half the amount of liquid in the IL 200 pen compared to the IL 100 pen (due to the concentration). Questionnaire items that were rated less important by participants who preferred the IL 200 pen do not suggest such attributes were deemed less important in a pen device, but rather did not exert as much influence over the preference decision. Insulin therapy, particularly injectable insulin therapy, is associated with several unique challenges that may negatively impact patient acceptability of treatment and consequently reduce adherence. 30 Patients who use insulin frequently have described how dosing is inflexible, how injections disrupt daily activities, and expressed dissatisfaction with the number of daily injections required. [31] [32] [33] Poor adherence, especially among patients with T2DM, is associated with more frequent dosing, 34, 35 complex dosing regimens (eg, number of therapies), and burden of administration. 35 Satisfaction with the insulin delivery device (a combined measure of ease of use, interference with daily activities, and social acceptability) has been found to be positively linked to patient self-efficacy in patients with T2DM. 36 A positive injection experience that is preferred by patients may lead to improved patient satisfaction, and therefore, better adherence to therapy, which in turn improves longer-term patient outcomes. Patients have indicated they would be more compliant with their insulin therapy if they can use a product to reduce injection-related pain. 31 Patients with diabetes who are more satisfied with treatment may be more likely to adhere to it, 37 so it is important to individualize treatment according to patient preferences so that treatment satisfaction is maximized. Because the IL 200 pen contains an increased strength formulation of insulin lispro where each dose from the IL 200 pen is delivered in half the volume of the IL 100 pen, the pen's glide force is reduced 23 and there are fewer pen transitions for the user. These benefits may help address the challenges associated with poor treatment adherence.
Although this study assessed patient preferences among intended users of the insulin pen devices, it was a simulated injection study limited to a single visit in a setting intended to mimic the environment where injections occur (ie, home, community settings, outpatient facilities). However, injections may also occur in other environments, such as restaurants or places of work. Because this study used simulated injections, we could not assess whether participants would perceive actual injections of the same unit dose differently (eg, if a higher concentration insulin injection would be less painful), which could influence preference. Further study is warranted to assess real-world injection. Although our study recruited participants with prior pen or vial and syringe experience, there was not enough statistical power to conduct a subanalysis on these patient populations; therefore, we cannot conclude whether there was a differential pattern of pen preference based on the prestudy use of a pen versus a syringe and vial. The questionnaire was not a validated instrument; however, cognitive debriefing testing of these measures was done in the intended population of patients who were using insulin to ensure the breadth and understanding of the preference question and attribute ratings.
Conclusions
In summary, patients with diabetes who require more than 20 daily mealtime insulin units or diabetes caregivers preferred the IL 200 pen to the IL 100 pen based on the total amount of insulin in the pen device, the ease of pressing the injection button, and amount of fluid injected. These findings suggest that a more concentrated insulin pen device may improve the mealtime insulin injection experience for patients using greater than 20 units a day of mealtime insulin.
Abbreviations CI, confidence interval; EU, European Union, IL100 pen, insulin lispro 100 units/mL prefilled pen; IL200 pen, insulin lispro 200 units/mL prefilled pen; SD, standard deviation; T2DM, type 2 diabetes mellitus.
